NCT02576574 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02576574
Title	Avelumab in First-line NSCLC (JAVELIN Lung 100)
Recruitment	Completed
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	EMD Serono Research & Development Institute, Inc.
Indications	lung non-small cell carcinoma
Therapies	Gemcitabine Paclitaxel Cisplatin Avelumab Pemetrexed Disodium Carboplatin
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| SVK \| ROU \| POL \| NZL \| NLD \| LTU \| LBN \| ITA \| ISR \| IRL \| HUN \| HRV \| GRC \| GBR \| FRA \| EST \| ESP \| DNK \| DEU \| CZE \| CYP \| CAN \| BRA \| BGR \| BEL \| AUS

NCT02576574
Clinical Trial Detail